Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2025-11-26
Summary
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Conditions
- Recurrent Burkitt Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent Gray-Zone Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mediastinal Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Burkitt Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Grade 1 Follicular Lymphoma
- Refractory Grade 2 Follicular Lymphoma
- Refractory Grade 3 Follicular Lymphoma
- Refractory Grade 3a Follicular Lymphoma
- Refractory Gray-Zone Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Mediastinal Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
Interventions
- BIOLOGICAL
-
Given IV
- DRUG
-
Given PO
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Joseph M Tuscano · City of Hope Comprehensive Cancer Center LAO
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-15
- Primary Completion
- 2025-11-24
- Completion
- 2025-11-24
Countries
- United States
Study Locations
More Related Trials
-
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
NCT01035463 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT01075321 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
NCT02910063 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
NCT02911142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT02213913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
NCT02109224 ·Status: TERMINATED ·Phase: PHASE1
-
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01116154 ·Status: TERMINATED ·Phase: PHASE1
-
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
NCT02869633 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT01060384 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NCT02875067 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT02992522 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00655668 ·Status: TERMINATED ·Phase: PHASE2
-
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT01838434 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
NCT02341014 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00179673 ·Status: COMPLETED ·Phase: PHASE2
-
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
NCT06723457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
NCT02561273 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
NCT03179930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02086604 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
NCT00413036 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
NCT00478959 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
NCT00704691 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
NCT00918333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2